Verified factor-similar pair

IVOV vs MDYV

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML
Similarity score
96
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • IVOV has the higher backtested relative Sharpe (0.934 vs 0.894).
  • IVOV has the lower published fee (0.10% vs 0.15%).
  • IVOV is cheaper on dividend valuation (114 vs 116, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

IVOV

Vanguard S&P Mid-Cap 400 Value ETF
SMB HML
Adj. R2
0.954
Rel. Sharpe
0.934
Mkt beta
1.00
AUM
US$1.2B
MER
0.10%
Valuation
114

MDYV

State Street SPDR S&P 400 Mid Cap Value ETF
SMB HML
Adj. R2
0.949
Rel. Sharpe
0.894
Mkt beta
0.98
AUM
US$2.5B
MER
0.15%
Valuation
116

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
IVOV
+0.52
|t|
+13.9
MDYV
+0.50
|t|
+14.2
diff +0.03
HML
IVOV
+0.34
|t|
+9.2
MDYV
+0.29
|t|
+8.5
diff +0.04
RMW
IVOV
+0.17
|t|
+4.0
MDYV
+0.17
|t|
+4.1
diff -0.00
CMA
IVOV
+0.02
|t|
+0.5
MDYV
+0.03
|t|
+0.6
diff -0.01
UMD
IVOV
-0.08
|t|
-3.2
MDYV
-0.07
|t|
-3.6
diff -0.01

Why This Pair Matches

Exposure level
96
Exposure shape
100
Mkt beta diff
0.02
Rel. Sharpe diff
0.039

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

IVOV fund page MDYV fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.